Top

Published in:

01-01-2009 | Preclinical Study

Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer

Authors: Kirsimari Aaltonen, Rose-Marie Amini, Göran Landberg, Hannaleena Eerola, Kristiina Aittomäki, Päivi Heikkilä, Heli Nevanlinna, Carl Blomqvist

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Abstract

Cyclins D1 and E play an important role in breast carcinogenesis. High cyclin E expression is common in hormone receptor negative and high grade aggressive breast cancer, whereas cyclin D1 in hormone receptor positive and low grade breast cancer. Experimental data has suggested that cyclin D1 and E mediate cell proliferation by different mechanisms in estrogen receptor (ER) positive and negative breast cancer. To test this hypotheses in large breast cancer material and to clarify the histopathological correlations of cyclin E and D1, especially the association with proliferation, we analyzed cyclin E and D1 immunohistochemical expression on breast tumour microarrays consisting of 1348 invasive breast cancers. High cyclin D1 expression was associated with high grade (P < 0.0005), high cyclin A (P < 0.0005) and Ki67 (P < 0.0005) expression among ER positive but with low grade (P = 0.05) and low Ki67 (P = 0.01) expression among ER negative breast cancers. Cyclin E and D1 expression correlated positively in ER positive (P < 0.0005) but had a negative correlation in ER negative tumours (P = 0.004). Cyclin E associated with high grade among all tumours (P < 0.0005). In conclusion, the findings of this study show that cyclin D1 has separate roles, and proliferation is driven by different mechanisms in ER positive and negative breast cancers.

Ekholm SV, Reed SI (2000) Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12:676–684PubMedCrossRef

Gillett C, Fantl V, Smith R et al (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812–1817PubMed

Michalides R, Hageman P, van Tinteren H et al (1996) A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73:728–734PubMed

van Diest PJ, Michalides RJ, Jannink L et al (1997) Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am J Pathol 150:705–711PubMed

Umekita Y, Ohi Y, Sagara Y, Yoshida H (2002) Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 98:415–418PubMedCrossRef

Hwang TS, Han HS, Hong YC et al (2003) Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int 53:74–80PubMedCrossRef

Han S, Park K, Bae BN et al (2003) Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Oncol Rep 10:141–144PubMed

Elsheikh S, Green AR, Aleskandarany MA et al (2007) CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat

Doisneau-Sixou SF, Sergio CM, Carroll JS et al (2003) Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10:179–186PubMedCrossRef

10.

Gillett C, Smith P, Gregory W et al (1996) Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69:92–99PubMedCrossRef

11.

Reis-Filho JS, Savage K, Lambros MB et al (2006) Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 19:999–1009PubMedCrossRef

12.

Stendahl M, Kronblad A, Ryden L et al (2004) Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90:1942–1948PubMedCrossRef

13.

Ahnstrom M, Nordenskjold B, Rutqvist LE et al (2005) Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Treat 91:145–151PubMedCrossRef

14.

Jirstrom K, Stendahl M, Ryden L et al (2005) Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 65:8009–8016PubMed

15.

Neuman E, Ladha MH, Lin N et al (1997) Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17:5338–5347PubMed

16.

Keyomarsi K, Conte D Jr, Toyofuku W et al (1995) Deregulation of cyclin E in breast cancer. Oncogene 11:941–950PubMed

17.

Nielsen NH, Arnerlov C, Emdin SO et al (1996) Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 74:874–880PubMed

18.

Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401:297–300PubMedCrossRef

19.

Keyomarsi K, Tucker SL, Buchholz TA et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566–1575PubMedCrossRef

20.

Han S, Park K, Bae BN et al (2003) Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol 83:241–247PubMedCrossRef

21.

Rudolph P, Kuhling H, Alm P et al (2003) Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 105:674–680PubMedCrossRef

22.

Kuhling H, Alm P, Olsson H et al (2003) Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 199:424–431PubMedCrossRef

23.

Lindahl T, Landberg G, Ahlgren J et al (2004) Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 25:375–380PubMedCrossRef

24.

Chappuis PO, Donato E, Goffin JR et al (2005) Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 16:735–742PubMedCrossRef

25.

Spruck C, Sun D, Fiegl H et al (2006) Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res 66:7355–7360PubMedCrossRef

26.

Sieuwerts AM, Look MP, Meijer-van Gelder ME et al (2006) Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 12:3319–3328PubMedCrossRef

27.

Span PN, Tjan-Heijnen VC, Manders P et al (2003) Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22:4898–4904PubMedCrossRef

28.

Akli S, Zheng PJ, Multani AS et al (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64:3198–3208PubMedCrossRef

29.

Desmedt C, Ouriaghli FE, Durbecq V et al (2006) Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. Int J Cancer 119:2539–2545PubMedCrossRef

30.

Porter PL, Barlow WE, Yeh IT et al (2006) p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 98:1723–1731PubMedCrossRef

31.

Loden M, Stighall M, Nielsen NH et al (2002) The cyclin D1 high and cyclin E high subgroups of breast cancer: Separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 21:4680–4690PubMedCrossRef

32.

Syrjakoski K, Vahteristo P, Eerola H et al (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected finnish breast cancer patients. J Natl Cancer Inst 92:1529–1531PubMedCrossRef

33.

Kilpivaara O, Bartkova J, Eerola H et al (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113:575–580PubMedCrossRef

34.

Eerola H, Blomqvist C, Pukkala E et al (2000) Familial breast cancer in southern finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 36:1143–1148PubMedCrossRef

35.

Eerola H, Heikkila P, Tamminen A et al (2005) Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7:R93–R100PubMedCrossRef

36.

Tanner M, Gancberg D, Di Leo A et al (2000) Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157:1467–1472PubMed

37.

Lassus H, Leminen A, Vayrynen A et al (2004) ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 92:31–39PubMedCrossRef

38.

Tommiska J, Eerola H, Heinonen M et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098–5103PubMedCrossRef

39.

Aaltonen K, Ahlin C, Amini RM et al (2006) Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides. Br J Cancer 94:1697–1702PubMed

40.

Ahlin C, Aaltonen K, Amini RM et al (2007) Ki-67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51:491–498PubMedCrossRef

41.

Lamb J, Ladha MH, McMahon C et al (2000) Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol 20:8667–8675PubMedCrossRef

42.

Grillo M, Bott MJ, Khandke N et al (2006) Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat 95:185–194PubMedCrossRef

43.

Berglund P, Stighall M, Jirstrom K et al (2007) Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern. J Clin Pathol

44.

Berglund P, Stighall M, Jirstrom K et al (2005) Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers. Cancer Res 65:9727–9734PubMedCrossRef

45.

Potemski P, Kusinska R, Watala C et al (2006) Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. J Exp Clin Cancer Res 25:59–64PubMed

Title: Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer
Authors: Kirsimari Aaltonen
Rose-Marie Amini
Göran Landberg
Hannaleena Eerola
Kristiina Aittomäki
Päivi Heikkilä
Heli Nevanlinna
Carl Blomqvist
Publication date: 01-01-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-9908-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression

Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive

Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model

Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast

A novel BRCA1 mutation in a Spanish patient with ovarian cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer